Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$9.2b

Bio-Rad Laboratories Past Earnings Performance

Past criteria checks 0/6

Bio-Rad Laboratories's earnings have been declining at an average annual rate of -43%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 2.5% per year.

Key information

-43.0%

Earnings growth rate

-43.2%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate2.5%
Return on equity-10.4%
Net Margin-30.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Dec 16
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Nov 25

Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

Nov 25
Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nov 04
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Sep 23

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Sep 08
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon

Jul 18
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Jul 14

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Apr 18
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Bio-Rad Labs reports Q4 2022 results

Feb 16

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

Revenue & Expenses Breakdown

How Bio-Rad Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:BIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,580-779800274
30 Jun 242,563-1,326797225
31 Mar 242,605-322809230
31 Dec 232,671-637824241
30 Sep 232,720-159843250
30 Jun 232,769-428853273
31 Mar 232,779-191854272
31 Dec 222,802-3,628825257
30 Sep 222,805-6,021808236
30 Jun 222,871-1,930814234
31 Mar 222,896-91821233
31 Dec 212,9234,254851247
30 Sep 212,9806,659875268
30 Jun 212,8804,045857263
31 Mar 212,7014,098832251
31 Dec 202,5463,814799218
30 Sep 202,3803,521784212
30 Jun 202,2941,947786200
31 Mar 202,3291,579798198
31 Dec 192,3121,759825203
30 Sep 192,304377817198
30 Jun 192,289905822200
31 Mar 192,292574831197
31 Dec 182,289366835199
30 Sep 182,2941,277835199
30 Jun 182,2831,030827212
31 Mar 182,212767827227
31 Dec 172,160122803235
30 Sep 172,11017819232
30 Jun 172,08513814220
31 Mar 172,09726798207
31 Dec 162,06826786206
30 Sep 162,06798776204
30 Jun 162,02897772198
31 Mar 162,018108768194
31 Dec 152,019109762193
30 Sep 152,047103769193
30 Jun 152,10897787203
31 Mar 152,139100796212
31 Dec 142,17589810220
30 Sep 142,17980828217
30 Jun 142,15461825217
31 Mar 142,14264820213
31 Dec 132,13378804211

Quality Earnings: BIO is currently unprofitable.

Growing Profit Margin: BIO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIO is unprofitable, and losses have increased over the past 5 years at a rate of 43% per year.

Accelerating Growth: Unable to compare BIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).

Return on Equity

High ROE: BIO has a negative Return on Equity (-10.4%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 20:28
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jon WoodBofA Global Research
Sel HardyCFRA Equity Research